Nantahala Capital Management LLC Invests $15.09 Million in Keros Therapeutics, Inc. $KROS

Nantahala Capital Management LLC purchased a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,410,419 shares of the company’s stock, valued at approximately $15,091,483. Nantahala Capital Management LLC owned 0.07% of Keros Therapeutics at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its position in Keros Therapeutics by 8.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after purchasing an additional 988 shares during the period. UBS Group AG lifted its stake in Keros Therapeutics by 1.1% in the third quarter. UBS Group AG now owns 103,864 shares of the company’s stock worth $1,643,000 after purchasing an additional 1,091 shares during the last quarter. Strs Ohio boosted its position in shares of Keros Therapeutics by 3.9% during the fourth quarter. Strs Ohio now owns 29,300 shares of the company’s stock valued at $597,000 after buying an additional 1,100 shares during the period. Caitong International Asset Management Co. Ltd boosted its position in shares of Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after buying an additional 1,166 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in shares of Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after buying an additional 1,888 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Keros Therapeutics

In other news, Director Nima Farzan sold 2,625 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the sale, the director owned 9,767 shares of the company’s stock, valued at approximately $104,799.91. This represents a 21.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Lorena Raquel Lerner sold 3,568 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total transaction of $36,714.72. Following the transaction, the insider owned 27,559 shares in the company, valued at approximately $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 13,768 shares of company stock worth $144,979 over the last quarter. 12.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on KROS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Wall Street Zen upgraded Keros Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 24th. Wells Fargo & Company reduced their target price on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 4th. Finally, Leerink Partners decreased their target price on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday, August 4th. Four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $20.50.

Keros Therapeutics Price Performance

NASDAQ:KROS opened at $11.03 on Friday. Keros Therapeutics, Inc. has a 1-year low of $9.69 and a 1-year high of $22.55. The company has a 50-day moving average of $10.78 and a 200 day moving average of $11.61. The firm has a market cap of $218.72 million, a PE ratio of -2.98 and a beta of 0.99.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. Sell-side analysts anticipate that Keros Therapeutics, Inc. will post -5.27 EPS for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.